Menu Search
Equities

Shionogi & Co Ltd

  • Add to watchlist
  • Add to portfolio
  • Add an alert
SH0:DUS

Shionogi & Co Ltd

Actions
  • Price (EUR)17.80
  • Today's Change-0.600 / -3.26%
  • Shares traded220.00
  • 1 Year change+31.85%
  • Beta0.5747
Data delayed at least 15 minutes, as of Feb 10 2026 18:30 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Shionogi & Co Ltd is a Japan-based company mainly engaged in the pharmaceutical business. The Company is mainly engaged in the research and development, purchasing, manufacturing, sales, and related activities of ethical pharmaceuticals. The Company is engaged in research and development, purchasing, manufacturing, and marketing of pharmaceuticals for the treatment of gram-negative bacterial infections, influenza virus infections, new coronavirus infections, invasive aspergillus infections, complicated urinary tract infections including pyelonephritis, Alzheimer's disease, chronic pain, cancer of the esophagus, bladder, head and neck, solid tumors, and other diseases. The Company provides products and services in Japan, Europe, North America, and other regions.

  • Revenue in JPY (TTM)465.35bn
  • Net income in JPY194.86bn
  • Incorporated1919
  • Employees4.96k
  • Location
    Shionogi & Co Ltd3-1-8, Dosho-machi, Chuo-kuOSAKA-SHI 541-0045JapanJPN
  • Phone+81 662022161
  • Fax+81 662299596
  • Websitehttps://www.shionogi.com/jp/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status		4507:TYO since
announced		Transaction
value
Japan Tobacco Inc-Pharmaceutical BusinessDeal completed07 May 202507 May 2025Deal completed42.21%37.90m
Data delayed at least 15 minutes, as of Feb 10 2026 06:30 GMT.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.